XTX Topco Ltd Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

XTX Topco Ltd reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 13.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,068 shares of the company’s stock after selling 10,459 shares during the quarter. XTX Topco Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,090,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of TEVA. Victory Capital Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 21.9% during the 4th quarter. Victory Capital Management Inc. now owns 38,386 shares of the company’s stock valued at $401,000 after purchasing an additional 6,886 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 31.5% in the fourth quarter. Private Advisor Group LLC now owns 19,424 shares of the company’s stock worth $204,000 after buying an additional 4,654 shares during the period. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 14.5% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,138 shares of the company’s stock valued at $168,000 after acquiring an additional 2,041 shares during the last quarter. Norges Bank purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $14,376,000. Finally, Hsbc Holdings PLC grew its position in Teva Pharmaceutical Industries by 242.6% during the 4th quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock worth $16,667,000 after acquiring an additional 1,130,969 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.4 %

NYSE:TEVA opened at $17.51 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $19.08. The company has a market capitalization of $19.83 billion, a PE ratio of -42.71, a P/E/G ratio of 1.26 and a beta of 0.88. The firm’s 50-day moving average price is $17.66 and its 200-day moving average price is $16.09. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now directly owns 45,060 shares of the company’s stock, valued at $777,285. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.55% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Bank of America raised their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.